|
DYPD genotyping to predict toxicity in patients with stage III colon cancer treated with 5-fluorouracil-based adjuvant chemotherapy in the PETACC-8 phase III trial. |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Honoraria - Merck Serono; Regeneron |
Consulting or Advisory Role - Merck Serono; Regeneron |
Research Funding - Merck serono (Inst); Regeneron (Inst) |
Travel, Accommodations, Expenses - merck serono |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Amgen; Lilly |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Stock and Other Ownership Interests - Bayer; Roche Pharma AG |
Honoraria - Amgen; AspenBio Pharma; Boehringer Ingelheim; Bristol-Myers Squibb; CSL Behring; GlaxoSmithKline; LEO Pharma; Roche Pharma AG |
Consulting or Advisory Role - Amgen; Baxter; Boehringer Ingelheim; GlaxoSmithKline; LEO Pharma |
Research Funding - LEO Pharma (Inst) |
|
|
Consulting or Advisory Role - Merck Serono |
Speakers' Bureau - Merck Serono |
Travel, Accommodations, Expenses - Merck Serono |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Merck Serono |
|
|
Research Funding - Novartis (Inst) |
Travel, Accommodations, Expenses - Bayer; Ipsen; Novartis |
|
|
Consulting or Advisory Role - Amgen; Celgene; Merck Serono; Roche/Genentech |
Research Funding - Pfizer (Inst); Roche/Genentech (Inst); Sanofi (Inst) |
Travel, Accommodations, Expenses - Amgen; Celgene; Merck Serono; Roche/Genentech |
|
|
Honoraria - Amgen; Boehringer Ingelheim; IntegraGen; Merck Serono; Sanofi |
Consulting or Advisory Role - Amgen; Boehringer Ingelheim; IntegraGen; Merck Serono; Sanofi |
Travel, Accommodations, Expenses - IntegraGen |